Cerebrospinal Fluid Levels of Chitinase 3-like 1 and Neurofilament Light Chain Predict Multiple Sclerosis Development and Disability After Optic Neuritis
Overview
Authors
Affiliations
Background: Cerebrospinal fluid (CSF) biomarkers have been suggested to predict multiple sclerosis (MS) after clinically isolated syndromes, but studies investigating long-term prognosis are needed.
Objective: To assess the predictive ability of CSF biomarkers with regard to MS development and long-term disability after optic neuritis (ON).
Methods: Eighty-six patients with ON as a first demyelinating event were included retrospectively. Magnetic resonance imaging (MRI), CSF leukocytes, immunoglobulin G index and oligoclonal bands were registered. CSF levels of chitinase-3-like-1, osteopontin, neurofilament light-chain, myelin basic protein, CCL2, CXCL10, CXCL13 and matrix metalloproteinase-9 were measured by enzyme-linked immunosorbent assay. Patients were followed up after 13.6 (range 9.6-19.4) years and 81.4% were examined, including Expanded Disability Status Scale and MS functional composite evaluation. 18.6% were interviewed by phone. Cox regression, multiple regression and Spearman correlation analyses were used.
Results: Forty-six (53.5%) developed clinically definite MS (CDMS) during follow-up. In a multivariate model MRI (p=0.0001), chitinase 3-like 1 (p=0.0033) and age (p=0.0194) combined predicted CDMS best. Neurofilament light-chain predicted long-term disability by the multiple sclerosis severity scale (p=0.0111) and nine-hole-peg-test (p=0.0202). Chitinase-3-like-1 predicted long-term cognitive impairment by the paced auditory serial addition test (p=0.0150).
Conclusion: Neurofilament light-chain and chitinase-3-like-1 were significant predictors of long-term physical and cognitive disability. Furthermore, chitinase-3-like-1 predicted CDMS development. Thus, these molecules hold promise as clinically valuable biomarkers after ON as a first demyelinating event.
Fluid biomarkers in multiple sclerosis: from current to future applications.
Di Filippo M, Gaetani L, Centonze D, Hegen H, Kuhle J, Teunissen C Lancet Reg Health Eur. 2024; 44:101009.
PMID: 39444698 PMC: 11496979. DOI: 10.1016/j.lanepe.2024.101009.
Passali M, Galea I, Knudsen M, Lau L, Cramer S, Frederiksen J J Neurol. 2024; 271(9):6127-6135.
PMID: 39052040 PMC: 11377639. DOI: 10.1007/s00415-024-12587-8.
Chitnis T, Qureshi F, Gehman V, Becich M, Bove R, Cree B Nat Commun. 2024; 15(1):4297.
PMID: 38769309 PMC: 11106245. DOI: 10.1038/s41467-024-48602-9.
Akesson J, Hojjati S, Hellberg S, Raffetseder J, Khademi M, Rynkowski R Nat Commun. 2023; 14(1):6903.
PMID: 37903821 PMC: 10616092. DOI: 10.1038/s41467-023-42682-9.
Talaat F, Abdelatty S, Ragaie C, Dahshan A Neurol Sci. 2023; 44(9):3243-3252.
PMID: 36988727 PMC: 10415417. DOI: 10.1007/s10072-023-06764-2.